BMO Capital reiterates Bristol-Myers Squibb stock rating at Market Perform

Bristol-Myers Squibb reported Q1 2026 EPS of $1.58 versus $1.42 expected and revenue of $11.49 billion versus $10.92 billion expected, supported by stronger Eliquis demand. BMO Capital reiterated a Market Perform rating, raised its price target to $60 from prior levels, and lifted 2026 revenue estimates to $16.4 billion from $16.1 billion. The outlook remains balanced, with pipeline readouts in 2H 2026 needed to offset revenue pressure from Revlimid, Pomalyst, and Eliquis loss of exclusivity.

Analysis

The market is starting to price BMY less like a melting-ice-cube and more like a slower-duration cash compounder, but that re-rating only holds if the company can keep pushing out the revenue cliff. The key second-order effect is that incremental durability in Eliquis and stronger near-term execution reduce the urgency for an immediate multiple collapse, yet they also raise the bar for the pipeline: investors will now treat 2026 clinical data as the real inflection point for whether the equity deserves anything above a low-teens earnings multiple.

The biggest overlooked winner may be the broader large-cap biotech basket, not BMY itself. If BMY can stabilize legacy erosion, it lowers perceived terminal-value risk across other pharma names facing LOE walls, while disappointing readouts later in 2026 would likely re-open the sector’s discount rate and punish companies with similar patent cliffs. In that sense, the stock is acting as a sentiment barometer for how much the market is willing to underwrite pipelines versus current cash flows.

For CYTK, the indirect read-through is more important than the headline mention: when BMY-related sentiment improves around a cardiology franchise, it can lift expectations for adjacent mechanism-heavy stories, but skepticism will remain high until hard trial differentiation emerges. BAC’s relevance is more tactical than fundamental; if investor positioning in healthcare improves, banks with underwriting exposure to the sector could see a mild risk-on bid, but this is too small to drive standalone P&L.

The contrarian angle is that the stock may be too cheap if the market is underestimating how long Eliquis and other mature assets can remain more resilient than expected. But the real downside risk is binary and delayed: if the 2H26 readouts disappoint, the multiple compression could happen much faster than the earnings erosion, because the market will have already granted BMY a bridge it has not yet earned.

Key Decisions for Investors

• Long BMY vs. short XBI for the next 6-9 months: capture idiosyncratic cash-flow stability while shorting the higher-beta biotech tape that is more exposed to trial disappointment. Risk/reward is attractive if BMY continues to re-rate on durability and the sector remains range-bound.
• Sell BMY upside calls or run a covered-call structure into the 2H26 catalyst window: the stock already has a partial recovery embedded, so upside likely stays capped until clinical data de-risks the bridge narrative. Best used with 60-90 day tenor.
• Buy a 2026 BMY put spread financed by near-dated calls if you want convexity around the clinical calendar: limited premium outlay against a potentially sharp de-rating if the pipeline fails to close the revenue gap. This is a good event-risk trade for accounts willing to wait.
• Relative value: long CYTK only on pullbacks, paired against BMY strength if sentiment over-extends on cardio/biotech optimism. The read-through is mostly sentiment-driven, so size should be small and tied to catalyst timing rather than fundamentals.
• Avoid chasing BAC off this healthcare spillover; any benefit is secondary and likely too small to matter. Better expressed through sector-beta exposure than through a single bank name.